Abstract OT2-09-01: TBCRC-055: A Phase II Study of NirAparib, Dostarlimab, and Radiotherapy in Metastatic, PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR) – NCT04837209
Elizabeth Scott(University of Indianapolis), Alice Ho(Breast Cancer Research Foundation), Carey K. Anders(Duke University), Neil K. Taunk, Rachel Blitzblau(Duke Medical Center), Alphonse G. Taghian(Massachusetts General Hospital), Payal D. Shah(Rutgers, The State University of New Jersey), Cesar Augusto Santa-Maria(Sidney Kimmel Comprehensive Cancer Center), Steven J. Isakoff(Harvard University), Gaorav P. Gupta(University of North Carolina at Chapel Hill), Jean L. Wright(University of North Carolina at Chapel Hill)
Cited by 3
Related Papers
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k